Overview

The emergency use provision in the Food and Drug Administration (FDA) regulations [21 CFR 56.104(c)] allows physicians a one time use, per institution, of an unapproved investigational drug, biologic, or device (referenced hereafter as “test article”). This OHRPP guidance and procedure document is intended to assist physicians by outlining the FDA emergency use requirements and the necessary procedures to ensure both the treatment of seriously ill patients in a life threatening situation and compliance with FDA regulatory requirements.

The FDA expects the physician to assess the potential benefits from the use of an unapproved device and to have substantial reason to believe that the benefits will exist in addition to determining whether the patient meets the qualifying criteria for emergency use.

IMPORTANT NOTES:

1. FDA and Department of Health and Human Services (DHHS) regulations differ:
   - **Under FDA regulations** although an emergency use is considered a “clinical investigation, it allows an exemption from IRB review. However, patients who receive a test article in an emergency use may not be considered a research participant.
   - **DHHS regulations** do not permit data obtained from patients who receive a test article in an emergency use to be classified as human participants research, nor do they permit the outcome of such care to be included in any report of a research activity subject to DHHS regulations.
2. Do not confuse “Emergency Use” with “Compassionate Use,” also known as “expanded access”. See links in definition below of “Expanded Access Programs”.

### Definitions and Terms

**Emergency Use:** The use of a test article (unapproved drug, biologic, or device) in a life-threatening situation where no standard acceptable treatment is available and there is not sufficient time to obtain IRB approval (21 CFR 56.102(d)). The FDA allows one emergency use per institution of a test article without prospective IRB review, and requires reporting of the emergency use to the IRB within 5 working days (21 CFR 56.104(c)). Generally, the emergency use of a test article requires either an IND (for unapproved drugs and biologics) or an IDE (for unapproved devices).

**Expanded Access Programs** is allowed only after prior review and approval by the IRB and, in most circumstances, prior approval by the FDA as well. Prior IRB approval is needed even if only one patient is to be treated under the any of the mechanisms of the expanded access to unapproved devices or drugs or biologics. See the section “Situations and Methods that Allow for Expanded Access to Unapproved Drugs for Treatment” in the OHRPP Guidance and Procedures: Use of Drugs and Biologics in Clinical Research and Treatment and OHRPP Guidance and Procedures: Use of Devices in Clinical Research and Treatment.

**Life-threatening:** Diseases or conditions where the likelihood of death is high unless the course of the disease is interrupted and diseases or conditions with potentially fatal outcomes, where the end point of clinical trial analysis is survival. The criteria for life-threatening do not require the condition to be immediately life-threatening or to immediately result in death. Rather, the recipients must be in a life-threatening situation requiring intervention before review at a convened meeting of the IRB is feasible.

**Severely debilitating** diseases or conditions cause major irreversible morbidity. Examples of severely debilitating conditions include blindness, loss of arm, leg, hand or foot, loss of hearing, paralysis or stroke.

**If there is sufficient time to obtain IRB approval:** In most cases, a **minimum** of three to five working days before a meeting is required for the Full Board to be able to review an emergency use application. For the purposes of this guidance, there is **sufficient time to obtain IRB approval** if the physician decides that the test article is **not** needed prior to the next scheduled Medical IRB meeting and the application for the use of the test article can be submitted at least three to five days prior to that meeting.

On the other hand, if there is insufficient time to prepare the application and to get it reviewed at Full Board before its use is needed to treat the life-threatening or potentially debilitating condition, then the emergency use without IRB approval criteria may be met. The clinician should not delay treatment if waiting for Full Board review would jeopardize the patient’s health or safety.

With the exception of holidays, there are usually six UCLA Medical IRB meetings per month. See the [UCLA IRB Meeting Calendar](#).

### Emergency Use Requirements (Step-by-Step Procedures)

The following is an overall summary the requirements (FDA regulations and UCLA policy) for emergency use of a test article.

**PRIOR USE REQUIREMENTS**
1. **Qualifying Criteria for Emergency Use:** All of the following five criteria must be met in order to comply with federal regulations and University policy:
   
   a. The patient has a condition that is *life-threatening or severely debilitating*,
   
   b. *No standard treatment* is available,
   
   c. There is *not sufficient time to obtain IRB review* and approval for an unapproved investigational drug, biologic, or device.
   
   d. This is the first emergency use of the test article (*one time per institution to treat a single patient*), and
   
   e. There is *no known available IRB approved study protocol* using the same test article or the patient cannot be enrolled into an existing protocol.

2. **For Drugs/Biologics:**
   
   a. **Contact the Sponsor/Manufacturer:** Determine whether the test article can be made available for the emergency use under the sponsor/manufacturer’s IND.

      **NOTE:** If the sponsor/manufacturer of the test article requires a letter from the IRB before shipping the test article, an acknowledgement letter of the emergency use can be provided (which should not be construed as IRB approval).

   b. **Contact the FDA:** If the manufacturer of a drug or biologic declines permission to use its IND, the physician may contact the FDA to obtain an IND at the numbers below (for drug or biologic). The physician may also contact the FDA for additional information and guidance, and for notification about the emergency use.

   c. **Contact the UCLA Investigational Drug Pharmacy:** If the emergency use involves a drug or biologic, you must comply with institutional policies regarding the receipt, storage, and dispensation of the drug/biologic. Please contact the UCLA Department of Pharmaceutical Services – Investigational Drug Section at (310) 267-8522 and ask to speak with an Investigational Drug Pharmacist.

3. **For Devices:**
   
   a. **The emergency use of any unapproved device may occur:**
      
      o When a physician wants to use the device in a way not approved under the IDE,
      
      o When a physician is not an investigator under the IDE, or
      
      o When an IDE for the device does not exist.

   b. **Contact the Sponsor/Manufacturer:** Obtain authorization from the IDE sponsor, if an IDE exists (if possible).

      **IMPORTANT NOTE:** **Contacting the FDA** for prior use notification or approval is *not* required for shipment or emergency use of the unapproved device. The FDA does not need to be notified prior to the emergency use of a device when a patient meets the criteria for emergency use.

   c. **If possible, seek an independent assessment** (written) of an uninvolved physician regarding the emergency use of the unapproved device.

4. **OHRPP/IRB Requirements:**
   
   a. **Check the List of Test Articles Used at UCLA in Previous Emergencies** to see if the test article has previously been used at UCLA

      o If the emergency test article has previously been used at UCLA, contact OHRPP to discuss your options at mirb@research.ucla.edu or (310) 825-5344.
b. Open, complete, and submit a new Bruin IRB application and indicate this as an emergency use application under the section study scope.
   - Submit the Emergency Use application in advance of use, if there is sufficient time for IRB review
   - OR
     Submit the Emergency Use application within 5 working days after use, if there is not sufficient time for IRB review

5. Obtain Informed consent: Written informed consent is required, and must be obtained from the patient or the patient’s legally authorized representative unless the criteria for an exception from the informed consent requirement is met, as described below in Obtaining Informed Consent for Emergency Use.

POST-USE REQUIREMENTS

1. Submit to the IRB within 5 working days after the test article use, if IRB approval was not obtained prior to use:

2. Notify the FDA and Sponsor/Manufacturer
   a. The physician must provide outcomes or safety information as required by the FDA.
   b. For Drugs/Biologics: If the treating physician is the IND holder, any follow-up information should be reported to the FDA.
   c. For Devices: The FDA requires the following post-use reporting:
     - If an IDE exists, the physician must provide the IDE sponsor a report. The sponsor is required to submit a report to the FDA within 5 working days the sponsor is aware of the emergency use.
     - If an IDE does not exist, the physician must submit a report to the FDA within 5 working days of device use.
     - The report should include a summary of the conditions constituting the emergency, the patient protections measures taken, and patient outcome information

3. The physician should consider possible future use of the test article at UCLA and, if necessary, initiate efforts to obtain IRB approval and regulatory clearance (IND or IDE) for such future uses.

FDA Contact Information

<table>
<thead>
<tr>
<th>Test Article</th>
<th>Office/Division</th>
<th>Phone</th>
<th>email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug (CDER)</td>
<td>Division of Drug Information</td>
<td>(301) 796-3400</td>
<td><a href="mailto:druginfo@fda.hhs.gov">druginfo@fda.hhs.gov</a></td>
</tr>
<tr>
<td>Biologic (CBER)</td>
<td>Office of Communication, Outreach and Development</td>
<td>(240) 432-8020</td>
<td><a href="mailto:Industry.biologics@fda.hhs.gov">Industry.biologics@fda.hhs.gov</a></td>
</tr>
<tr>
<td>Device</td>
<td>Office of Device Evaluation</td>
<td>(301) 796-7100</td>
<td><a href="mailto:dice@fda.hhs.gov">dice@fda.hhs.gov</a></td>
</tr>
<tr>
<td>After Normal Working Hours</td>
<td>Office of Emergency Operations</td>
<td>(866) 300-4374</td>
<td><a href="mailto:emergency.operations@fda.hhs.gov">emergency.operations@fda.hhs.gov</a></td>
</tr>
</tbody>
</table>

NOTE: UCLA CTSI Office of Regulatory Affairs can provide FDA guidance, support, and assistance with FDA communication for investigators.

Obtaining Informed Consent for Emergency Use
• **Written informed consent for emergency use of a test article must be obtained** from the patient or legally authorized representative. See [OHRPP Guidance and Procedure: Obtaining and Documenting Informed Consent](#).

• **Exception from the informed consent requirement** may occur if both the treating physician and a physician not otherwise involved in the emergency use, certify in writing that **all of the following criteria are met** (21 CFR 50.23(a)):
  
  o The prospective recipient is confronted by a life-threatening situation necessitating the use of the test article.
  
  o Informed consent cannot be obtained from the recipient because of an inability to communicate with, or obtain legally effective consent from, the recipient.
  
  o Time is not sufficient to obtain consent from the recipient’s legal representative.
  
  o There is no available alternative method of approved or generally recognized therapy that provides an equal or greater likelihood of saving the life of the recipient.

• If there is not sufficient time to obtain an independent written certification of the criteria for an exception from informed consent prior to the use of the test article, the determinations of the treating physician must be made, reviewed and evaluated in writing by a physician who is not involved in the emergency use, and submitted to the IRB within 5 working days after the emergency use of the test article (21 CFR 50.23(b) and 21 CFR 50.23(c)).

### IRB Procedures

The OHRPP/IRB maintains a current List of Previous Emergency Uses of Test Articles on the OHRPP web site for reference. The database and list are updated after each emergency use of a test article reported to OHRPP/IRB.

### Prior Use Procedures

• The MIRB Chair’s concurrence with the treating physician (if obtained) will be communicated by the MIRB Chair through BruinIRB.

### Protocol Requirements

The IRB requires the following information to be included in the protocol upon submission of the emergency use application. The protocol must address the following:

- Describe the patients’ medical condition
- Explain why standard acceptable treatments could not be used
- If the emergency use of the test article has already been used, indicate the date when the test article was used
- If the emergency use of the test article has not been used, indicate the target treatment date

See OHRPP [Emergency Use protocol template](#).

Non-compliance with emergency use requirements will be processed as described in OHRPP Policy: Noncompliance and Allegations of Noncompliance Regarding the Conduct of Human Subjects Research.

### Regulations and References

**FDA References**
• FDA IDE Early/Expanded Access – Emergency Use
• FDA Physician Request for an Individual Patient IND under Expanded Access for Non-emergency or Emergency Use
• FDA Center for Devices and Radiological Health Training Presentation: Institutional Review Board – Compassionate and Emergency Use

FDA Regulations
• Exception from general requirements of informed consent 21 CFR 50.23(a) – (c)
• Exception from informed consent requirements 21 CFR 50.24
• Definition of Emergency Use 21 CFR 56.102(d)
• Exemption from IRB review 21 CFR 56.104(c)
• Expanded access to individual patients for emergency use 21 CFR 312.310
• Emergency use of a device and reporting to FDA 21 CRF 812.35(a)(2)
• Treatment use of an investigational device 21 CFR 812.36

UCLA References:
• UCLA CTSI Office of Regulatory Affairs

Change history:
03/12/2021: Added BruinIRB information and updated links.
02/06/2023: Updated the List of Previous Emergency Uses of Test Articles links.